Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

Influenza Clinical Trial

Official title:

Immunogenicity and Safety of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01215669
• Other study ID #: GID33
• Secondary ID: U111111156473
• Status: Completed
• Phase: Phase 4
• Start date: October 2010
• Est. completion date: April 2011

Study information

• Verified date: September 2018
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to assess the immunogenicity and safety of the 2010-2011 NH season formulation of intradermal (ID) influenza vaccine as part of a post registration commitment.

Objectives:

• For all groups, to evaluate compliance, in terms of immunogenicity, of the corresponding strength of the intradermal (ID) or intramuscular (IM) influenza vaccine Northern Hemisphere (NH) 2010 2011 formulation with the requirements of the Committee for Human Medicinal Products (CHMP) Note for Guidance (NfG) CPMP/BWP/214/96

• For all groups, to describe the safety

Description:

All participants will receive a single dose of study vaccine on Day 0. Immunogenicity data will be collected before vaccination and on Day 21 post vaccination. Safety will be assessed throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: April 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 years and over on the day of inclusion

• Informed consent form has been signed and dated

• Able to attend all scheduled visits and to comply with all trial procedures

• For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination.

Exclusion Criteria:

• Known systemic hypersensitivity to eggs, chicken proteins, neomycin, formaldehyde and octoxynol-9, or to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances

• Known pregnancy, or a positive urine pregnancy test

• Currently breastfeeding a child

• History of seasonal influenza vaccination within the previous 6 months (other than pandemic H1N1 influenza vaccine)

• Receipt of an influenza vaccine (either seasonal or pandemic vaccine) in a clinical trial within the previous 12 months

• Known or suspected congenital or acquired immunodeficiency, resulting for example from: end-stage renal disease requiring dialysis; active neoplastic disease or active hematologic malignancy; receipt of immunosuppressive therapy or other immune-modifying drugs such as, but not limited to anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

• History of seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C

• Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response

• Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion

• History of thrombocytopenia, contraindicating intramuscular (IM) vaccination

• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination, under the investigator's judgment

• Receipt of any vaccine in the 4 weeks preceding the trial vaccination

• Planned receipt of any vaccine in the 3 weeks following the trial vaccination

• Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination

• Planned participation in another clinical trial during the present trial period

• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily

• Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures

• Identified as employees of the Investigator or study department, with direct involvement in the proposed study or other studies under the direction of that Investigator or study department as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• IDflu™: Split virion inactivated influenza vaccine
Single dose 0.1 mL, intradermal
• Vaxigrip®: Split virion inactivated influenza vaccine
Single dose 0.5 mL, intramuscular
• IDflu™: Split virion inactivated influenza vaccine
Single dose 0.1 mL, intradermal
• Vaxigrip®: Split virion inactivated influenza vaccine
Single dose 0.5 mL, intramuscular

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (1)

Hoon Han S, Hee Woo J, Weber F, Joo Kim W, Ran Peck K, Il Kim S, Hwa Choi Y, Myung Kim J. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial. Hum Vaccin Immunother. 2013 S — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Information concerning the immunogenicity of intradermal influenza vaccine in terms of seroprotection status (titers =40) using the Hemagglutination Inhibition (HAI) technique.		21 days post-vaccination
Primary	Information regarding the safety (in terms of solicited injection site and systemic reactions) post-vaccination		Day 0 to up to 21 days post-vaccination